Based on the Guidelines for Clinical Diagnosis and Treatment of Advanced Breast Cancer in China (2020 edition), the China Advanced Breast Cancer Guideline Panel updated the 2022 edition of this guideline under the guidance of the Breast Cancer Expert Committee of National Cancer Quality Control ...
Guideline Panel discussed and summarized recent clinical evidence, updated the guidelines for the diagnosis and treatment of advanced breast cancer based on the 2020 edition, and formulated the "Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)" for clinicians' ...
as well as growing crude incidence and mortality of cancer.Breast cancer is the most common cancer type in females in China and the incidence rate for breast cancer in Chinese females has increased during the last two decades.However, breast cancer prognosis in China is poorer than that in ...
Advances in medical treatment of breast cancer in 2022 Jingtong Zhai, Cancer Innovation, 2023 COVID-19 vaccine development: milestones, lessons and prospects Maochen Li, Signal Transduction and Targeted Therapy, 2022 Effects of COVID-19 fear and anxiety on attitudes towards compleme...
[12] Peccatori FA, Azim Ha JR, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2013, 24 (suppl 6): vi160-170. ...
December 10th 2022 Following a phase 2 analysis of OP-1250 with palbociclib, researchers recommend an OP-1250 dose level of 120 mg/day for future trials. Watch Breast Cancer Specialist Says Guidelines for HER2 Cancer Subtypes Can Optimize Patient Treatment ...
2022;114(2):263-270. doi:10.1093/jnci/djab186PubMedGoogle ScholarCrossref 26. Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319(2):154-164. doi:...
Over the period studied, adjuvant breast cancer treatment adhered to the guidelines of the Danish Breast Cancer Cooperative Group (www.dbcg.dk). There was no population-based mammography screening in the study area. Moreover, there were no major changes to diagnostic techniques in the study ...
[3] Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690 [4] S. Modi, W. Jacot, 376...
由此看来,不管是2022 年ESMO大会公布的PRO分析数据,还是本次ESMO BC公布的详细安全性数据,都共同揭示了DESTINY-Breast04研究中,T-DXd治疗HER2低表达晚期乳腺癌的良好安全性特征。并且,随着时间的推移,研究者对T-DXd治疗相关ILD事件的认知度不断提高,对其管理经验也愈加丰富,同时相关指南/共识也逐渐在完善,其发生率和...